Litcius/Paper detail

Long-lasting CRs after ibrutinib monotherapy for relapse or refractory primary CNS lymphoma (PCNSL) and primary vitreoretinal lymphoma (PVRL): Long-term results of the iLOC study by the Lymphoma Study Association (LYSA) and the French Oculo-Cerebral Lymphoma (LOC) Network (clinical trial number: NCT02542514)

Carole Soussain, Denis Malaise, Sylvain Choquet, Hervé Ghesquières, Caroline Houillier

2023European Journal of Cancer15 citationsDOI

Topics & Concepts

IbrutinibLymphomaPrimary central nervous system lymphomaMedicineDiffuse large B-cell lymphomaOncologyInternal medicineRefractory (planetary science)LeukemiaBiologyChronic lymphocytic leukemiaAstrobiologyCNS Lymphoma Diagnosis and TreatmentLymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia Research
Long-lasting CRs after ibrutinib monotherapy for relapse or refractory primary CNS lymphoma (PCNSL) and primary vitreoretinal lymphoma (PVRL): Long-term results of the iLOC study by the Lymphoma Study Association (LYSA) and the French Oculo-Cerebral Lymphoma (LOC) Network (clinical trial number: NCT02542514) | Litcius